Literature DB >> 7870050

Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.

M J Rogers1, X Xiong, R J Brown, D J Watts, R G Russell, A V Bayless, F H Ebetino.   

Abstract

The mechanisms by which bisphosphonate drugs inhibit osteoclast-mediated bone resorption are unclear. Effects of bisphosphonates on cellular enzymes, metabolic pathways, and osteoclast morphology have previously been described and could culminate in a generalized cytotoxic effect or a decreased capacity of osteoclasts to resorb bone. Recent studies of the structure-activity relationship for the bisphosphonate side chain indicate, however, that at least the newer generations of nitrogen-containing bisphosphonates probably act by binding to a specific target at a site that is complementary in structure to the bisphosphonate side chain. We have previously proposed that such a target for bisphosphonates is also present in amoebae of the cellular slime mold Dictyostelium discoideum, because growth of this microorganism is inhibited by a wide range of bisphosphonates in a manner that closely reflects the antiresorptive potencies of the bisphosphonates in vivo. We have added support for this view by examining the potency towards Dictyostelium of bisphosphonates in which slight changes in the structure of the side chain or conformational restrictions to the side chain have marked effects on antiresorptive potency. The changes in the side chain that affected the in vivo antiresorptive potency of the bisphosphonates consistently affected in a similar manner the potency of the bisphosphonates as inhibitors of the growth of Dictyostelium amoebae. These observations confirm that bisphosphonate drugs have a molecular target that is common to both Dictyostelium amoebae and osteoclasts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7870050

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

1.  Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate.

Authors:  Aurora Ortiz-Gómez; Carmen Jiménez; Antonio M Estévez; Juana Carrero-Lérida; Luis M Ruiz-Pérez; Dolores González-Pacanowska
Journal:  Eukaryot Cell       Date:  2006-07

2.  Structural aspects of the effectiveness of bisphosphonates as competitive inhibitors of the plant vacuolar proton-pumping pyrophosphatase.

Authors:  R Gordon-Weeks; S Parmar; T G Davies; R A Leigh
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

3.  Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake.

Authors:  M J Rogers; X Xiong; X Ji; J Mönkkönen; R G Russell; M P Williamson; F H Ebetino; D J Watts
Journal:  Pharm Res       Date:  1997-05       Impact factor: 4.200

4.  Clodronate acts on human osteoclastic cell proliferation, differentiation and function in a bioreversible manner.

Authors:  Raffaella Recenti; Giuseppe Leone; Lisa Simi; Marco Orfei; Pamela Pinzani; Giuseppe Pieraccini; Gloriano Moneti; Anna Maria Carossino; Alessandro Franchi; Gianluca Bartolucci; Silvia Carbonell Sala; Mauro Ginanneschi; Annalisa Tanini; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2007-05

5.  Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.

Authors:  Luigi Sinigaglia; Massimo Varenna; Silvia Casari
Journal:  Clin Cases Miner Bone Metab       Date:  2007-01

6.  Targeting Cancer Cells with a Bisphosphonate Prodrug.

Authors:  Kenji Matsumoto; Kosuke Hayashi; Kaoru Murata-Hirai; Masashi Iwasaki; Haruki Okamura; Nagahiro Minato; Craig T Morita; Yoshimasa Tanaka
Journal:  ChemMedChem       Date:  2016-10-27       Impact factor: 3.466

Review 7.  Bisphosphonates in bone diseases.

Authors:  R W Sparidans; I M Twiss; S Talbot
Journal:  Pharm World Sci       Date:  1998-10

8.  Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.

Authors:  J E Fisher; M J Rogers; J M Halasy; S P Luckman; D E Hughes; P J Masarachia; G Wesolowski; R G Russell; G A Rodan; A A Reszka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

9.  Farnesyl diphosphate synthase, the target for nitrogen-containing bisphosphonate drugs, is a peroxisomal enzyme in the model system Dictyostelium discoideum.

Authors:  James M Nuttall; Ewald H Hettema; Donald J Watts
Journal:  Biochem J       Date:  2012-11-01       Impact factor: 3.857

10.  Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.

Authors:  Yoshimasa Tanaka; Masashi Iwasaki; Kaoru Murata-Hirai; Kenji Matsumoto; Kosuke Hayashi; Haruki Okamura; Tomoharu Sugie; Nagahiro Minato; Craig T Morita; Masakazu Toi
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.